C-Path is excited to welcome CND Life Sciences as the newest member of it Critical Path for Parkinson’s (CPP) Consortium. CND Life Sciences leads scientific discovery, having developed the first and only skin-based test to detect misfolded alpha-synuclein to support diagnostic efforts across neurodegenerative diseases, including Parkinson’s disease and related disorders. With a patient-first approach and an emphasis on partnering with biopharma companies, CND Life Sciences is committed to optimizing clinical trials and ensuring convenient, objective, and precise diagnostic tools and reliable biomarkers are integrated for the right patients in the right trials. CPP is excited to partner with CND Life Sciences as one of the many new members from around the globe that are advancing solutions for Parkinson’s.
